Antihistamine OTC Switch: FDA Asking If Rx Products Have "Unique" Aspects
This article was originally published in The Tan Sheet
Executive Summary
FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.
You may also be interested in...
Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.
Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.
Antihistamine Safety Questions, Liability Risks Cautioned By Aventis
A switch of Allegra to nonprescription status could create the potential for unknown consumer risks and open the door to costly lawsuits, Aventis Senior VP-Medical & Regulatory Affairs Francois Nader, MD, suggested to a joint FDA advisory panel.